Latest filings (excl ownership)
15-12B
Securities registration termination
1 Feb 21
EFFECT
Notice of effectiveness
27 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
22 Jan 21
POS AM
Prospectus update (post-effective amendment)
22 Jan 21
8-K
Completion of Acquisition or Disposition of Assets
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
22 Jan 21
25-NSE
Exchange delisting
22 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
22 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
20 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
20 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
14 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
14 Jan 21
SC 14D9/A
Tender offer solicitation (amended)
5 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
5 Jan 21
UPLOAD
Letter from SEC
4 Jan 21
SC 14D9
Tender offer solicitation
22 Dec 20
SC TO-T
Third party tender offer statement
22 Dec 20
SC14D9C
Written communication relating to third party tender offer
15 Dec 20
8-K
Lilly Announces Agreement to Acquire Prevail Therapeutics
15 Dec 20
SC TO-C
Information about tender offer
15 Dec 20
10-Q
2020 Q3
Quarterly report
13 Nov 20
8-K
Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
13 Nov 20
8-K
Regulation FD Disclosure
12 Nov 20
8-K
Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO
2 Nov 20
8-K
Prevail Therapeutics Announces Appointment of William H. Carson, M.D., to Board of Directors
10 Sep 20
424B5
Prospectus supplement for primary offering
11 Aug 20
10-Q
2020 Q2
Quarterly report
11 Aug 20
8-K
Prevail Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
11 Aug 20
EFFECT
Notice of effectiveness
9 Jul 20
UPLOAD
Letter from SEC
7 Jul 20
CORRESP
Correspondence with SEC
6 Jul 20
S-3
Shelf registration
1 Jul 20
8-K
Submission of Matters to a Vote of Security Holders
17 Jun 20
10-Q
2020 Q1
Quarterly report
14 May 20
8-K
Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights
14 May 20
DEFA14A
Additional proxy soliciting materials
27 Apr 20
DEF 14A
Definitive proxy
27 Apr 20
S-8
Registration of securities for employees
26 Mar 20
10-K
2019 FY
Annual report
26 Mar 20
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
16 Feb 21
SC 13G/A
CITADEL ADVISORS LLC
16 Feb 21
SC 13G/A
EcoR1 Capital, LLC
12 Feb 21
SC 13G/A
REGENXBIO Inc.
12 Feb 21
SC 13G
JNE Partners LLP
29 Jan 21
SC 13D/A
ORBIMED ADVISORS LLC
29 Jan 21
4
Change in insider ownership
26 Jan 21
4
Asa Abeliovich
26 Jan 21
4
Timothy M Adams
26 Jan 21
4
William H. Carson
26 Jan 21
4
Yong Dai
26 Jan 21
4
Franz Hefti
26 Jan 21
4
Brett Kaplan
26 Jan 21
4
Emily Minkow
26 Jan 21
4
Francois Nader
26 Jan 21
4
Kira M. Schwartz
26 Jan 21
4
Jeffrey Sevigny
26 Jan 21
4
Morgan Sheng
26 Jan 21
4
Ran Nussbaum
26 Jan 21
4
CARL L GORDON
26 Jan 21
4
Peter A. Thompson
26 Jan 21
4
Change in insider ownership
22 Jan 21
4
Asa Abeliovich
31 Dec 20
SC 13D
ELI LILLY & Co
22 Dec 20
3
Initial statement of insider ownership
16 Dec 20
SC 13G
CITADEL ADVISORS LLC
8 Oct 20
4
William H. Carson
11 Sep 20
3
William H. Carson
11 Sep 20
4
Peter A. Thompson
19 Jun 20
4
Morgan Sheng
19 Jun 20
4
Ran Nussbaum
19 Jun 20
4
CARL L GORDON
19 Jun 20
4
Timothy M Adams
19 Jun 20
4
Francois Nader
19 Jun 20
4
Kira M. Schwartz
3 Jun 20
3
Kira M. Schwartz
3 Jun 20
4
Yong Dai
11 Mar 20
4
Franz Hefti
11 Mar 20
4
Emily Minkow
11 Mar 20
4
Brett Kaplan
11 Mar 20